A detailed history of Birchview Capital, LP transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Birchview Capital, LP holds 209,574 shares of PRTA stock, worth $2.86 Million. This represents 3.23% of its overall portfolio holdings.

Number of Shares
209,574
Previous 203,574 2.95%
Holding current value
$2.86 Million
Previous $4.2 Million 16.54%
% of portfolio
3.23%
Previous 4.2%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.73 - $24.79 $100,380 - $148,740
6,000 Added 2.95%
209,574 $3.51 Million
Q2 2024

Aug 13, 2024

BUY
$19.54 - $26.15 $664,360 - $889,100
34,000 Added 20.05%
203,574 $4.2 Million
Q3 2023

Nov 14, 2023

BUY
$47.3 - $70.6 $636,799 - $950,487
13,463 Added 8.62%
169,574 $8.18 Million
Q2 2023

Aug 08, 2023

BUY
$48.26 - $78.59 $1.34 Million - $2.18 Million
27,716 Added 21.59%
156,111 $10.7 Million
Q1 2023

May 12, 2023

BUY
$46.97 - $58.27 $56,364 - $69,924
1,200 Added 0.94%
128,395 $6.22 Million
Q4 2022

Feb 03, 2023

BUY
$52.05 - $65.0 $429,412 - $536,250
8,250 Added 6.94%
127,195 $7.66 Million
Q3 2022

Nov 07, 2022

BUY
$25.16 - $60.63 $412,548 - $994,150
16,397 Added 15.99%
118,945 $7.21 Million
Q2 2022

Aug 12, 2022

BUY
$22.73 - $39.98 $1.38 Million - $2.42 Million
60,570 Added 144.29%
102,548 $2.78 Million
Q1 2022

May 13, 2022

BUY
$30.27 - $49.22 $52,397 - $85,199
1,731 Added 4.3%
41,978 $1.54 Million
Q3 2021

Nov 12, 2021

BUY
$48.2 - $78.89 $482,000 - $788,900
10,000 Added 33.06%
40,247 $2.87 Million
Q2 2021

Aug 10, 2021

BUY
$21.63 - $57.65 $654,242 - $1.74 Million
30,247 New
30,247 $1.56 Million
Q4 2017

Feb 02, 2018

SELL
$35.44 - $63.76 $128,718 - $231,576
-3,632 Closed
0 $0
Q3 2017

Nov 02, 2017

BUY
$53.83 - $67.75 $195,510 - $246,068
3,632
3,632 $235,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $641M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Birchview Capital, LP Portfolio

Follow Birchview Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Birchview Capital, LP with notifications on news.